Dr. Messer is Professor of Biostatistics at UCSD, and was Chief of the Division of Biostatistics from 2013 to 2022. She has been Director of the Biostatistics Shared Resource at UCSD Moores Cancer Center since 2006. Her research interests include causal inference, survey statistics, and innovative clinical trial designs. She has particular expertise in the epidemiology of tobacco use.
Dr. A. Eden Evins is the William Cox Family Professor of Psychiatry in the Field of Addiction Medicine at Harvard Medical School and founding director of the Center for Addiction Medicine and the Addiction Research Program of Massachusetts General Hospital (MGH). She is a member of the Schizophrenia Clinical and Research Program and the Depression Clinical and Research Program of MGH.
Dr. Evins earned her undergraduate degree at the University of
Virginia and her medical degree at the Medical University of South Carolina in Charleston. She completed an internship in Pediatric Medicine at the Children’s National Medical Center in Washington DC and her residency in psychiatry at Massachusetts Mental Health Center and Harvard-Longwood Psychiatry Residency Training Program in Boston, where she was also chief resident. She conducted a fellowship in molecular biology at the Mailman Research Center of McLean Hospital and a second fellowship in clinical and translational research at MGH with Dr. Don Goff. She received a Master’s in Public Health in Clinical Effectiveness from the Harvard School of Public Health.
Dr. Evins’ research interests include development of novel pharmacologic and behavioral treatments for nicotine dependence, cannabis dependence and for prevention of relapse to addictive disorders in those with and without co-occurring psychiatric illness. Her research pursuits include study of the cognitive effects of nicotine and of cannabis, and development pharmacotherapy for addictive disorders and for negative symptoms and cognitive dysfunction in schizophrenia. She has authored articles published in prestigious scientific journals, such as The Lancet, JAMA, JAMA Psychiatry, Biological Psychiatry, American Journal of Psychiatry, Neuropsychopharmacology, Addiction and the Journal of Clinical Psychiatry.
Dr. Evins has received three career awards from the National Institute on Drug Abuse (NIDA) of the National Institute of Health (NIH). She serves as a director of a Mass General based NIDA K12 Fellowship Training Program in Addiction Medicine. She is currently funded by grants from NIDA, NCI, NIMH, and PCORI.
Adam Leventhal, Ph.D. is University Professor in the Keck School of Medicine of the University of Southern California (USC). He is a clinical psychologist, public health scientist, and academic administrator who advances research, education, practice, and policy that reduces addiction. He leads the USC Institute for Addiction Science, which supports transdisciplinary collaborative addiction research, education, and community engagement across 8 schools and colleges within the university and various partnering organizations. Dr. Leventhal has authored over 400 scientific articles on the causes, treatment, prevention, and consequences of addiction to nicotine, cannabis, and other drugs across the lifespan. Recent work focuses on translating science to policy for effective regulation of tobacco and other addictive consumer products. He is also active in public health service, having served in advisory roles for the US Food and Drug Administration, Surgeon General, and White House Office of National Drug Control Policy, and the World Health Organization to inform tobacco and other drug policies.
SCLC’s annual Year in Review webinar highlights trends in tobacco cessation from the past year along with key advancements and opportunities in addressing tobacco use among disproportionately impacted populations.
The 2025 year in review will focus on three studies published in 2025 that examine nicotine product use and cessation efforts among adults and youth.
E-cigarettes have been marketed as tools to aid cigarette smoking cessation, driving increased demand among adults, despite limited population-level evidence supporting their effectiveness for cessation. The widespread availability and easy access to e-cigarettes among youth underscores the need for vaping cessation interventions. Additionally, the continued evolution of nicotine products presents new challenges and implications for youth populations.
Join us as we reflect on these important developments from the past year and explore the latest evidence that can help inform your practice.
Learning Objectives:
By the end of this webinar, participants will be able to:
- Explain the relationship between e-cigarette use and smoking cessation, among U.S. adults who smoke and use e-cigarettes.
- Describe the results of a randomized controlled trial of a vaping cessation intervention that includes varenicline, brief cessation counseling, and text messaging support for young people aged 16 to 25 years.
- Describe the prevalence trends in youth nicotine pouch and e-cigarette use in the United States.
Participants who join the live session on January 22, 2026, can earn 1.5 hours of free credit You will receive instructions on how to claim credit via the post-webinar email.
ACCME Accreditation
In support of improving patient care, the University of California, San Francisco is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
UCSF designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the webinar activity.
Advance Practice Registered Nurses and Registered Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 CreditTM issued by organizations accredited by the ACCME.
Physician Assistants: The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 CreditTM are acceptable for continuing medical education requirements for recertification.
California Pharmacists: The California Board of Pharmacy accepts as continuing professional education those courses that meet the standard of relevance to pharmacy practice and have been approved for AMA PRA category 1 CreditTM. If you are a pharmacist in another state, you should check with your state board for approval of this credit.
California Psychologists: The California Board of Psychology recognizes and accepts for continuing education credit courses that are provided by entities approved by the Accreditation Council for Continuing Medical Education (ACCME). AMA PRA Category 1 CreditTM is acceptable to meeting the CE requirements for the California Board of Psychology. Providers in other states should check with their state boards for acceptance of CME credit.
APA: Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs.
Up to 1.5 CE Credits may be claimed.
ASWB: As a Jointly Accredited Organization, UCSF Continuing Education is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.5 general continuing education credits.
Interprofessional Continuing Education Credit (IPCE): This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning and change.
Disclosures
This UCSF CME activity was planned and developed to uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.
All speakers, planning committee members and reviewers have disclosed they have no relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Catherine Bonniot, Christine Cheng, Brian Clark, Jennifer Matekuare, Ma Krisanta Pamatmat, MPH, CHES, Jessica Safier, MA, Jason Satterfield, PhD, and Maya Vijayaraghavan, MD, MAS.
Don’t need to claim CME/CEUs? SCLC issues free certificates of attendance for those who want contact hours only.